



Program advice for health professionals

Key points and updates for 1 July 2024

- The National Immunisation Program (NIP) provides free meningococcal ACWY vaccines to people to protect them against four types of meningococcal disease, A, C, W and Y.
- From 1 July 2024, MenQuadfi® will be funded under the NIP for adolescents aged 14 to 16 years and those aged 15 to 19 years on catch-up schedules.
- Vaccines will be delivered through school vaccination programs and health services, including pharmacies, for those young people on catch-up schedules.
- There is no change to NIP funded meningococcal ACWY vaccines for any other cohort. Children aged 12 months and people with specified medical conditions will continue to receive Nimenrix®.
- It is mandatory to report all meningococcal ACWY vaccines you have administered to the Australian Immunisation Register (AIR).

Vaccines

From 1 July 2024, the NIP will fund the following meningococcal ACWY vaccines:

- Nimenrix®
- MenQuadfi®

Dosing

Healthy children and adolescents are recommended to receive a single dose of meningococcal ACWY vaccine at 12 months and between 14 to 19 years.

People with specified medical conditions are recommended to receive extra doses compared with people who do not have these conditions.

For more information, see [The Australian Immunisation Handbook](#).

Children

All children aged 12 months are strongly recommended to receive a single dose of Nimenrix® vaccine for free through the NIP from their health professional or health service.

Adolescents

Adolescents aged 14 to 16 years are recommended to receive a single dose of MenQuadfi® for free primarily through school-based vaccination programs or other health services.

Young people aged 15 to 19 years on catch-up schedules can receive a single dose of MenQuadfi® for free from their health professional or through a range of health services including pharmacies.

Medically at-risk

A single dose of Nimenrix® is free through the NIP for people of all ages with:

- asplenia and hyposplenia
- complement deficiency, and
- those receiving treatment with eculizumab.

Vaccine safety

Contraindications

Meningococcal ACWY vaccines should not be given to people who have had:

- anaphylaxis after a previous dose of any meningococcal vaccine
- anaphylaxis after any component of a meningococcal vaccine.

Meningococcal ACWY vaccines are not generally recommended for people who are pregnant or breastfeeding.

Adverse events following vaccination

You must notify of all adverse events following immunisation through the usual reporting mechanisms in your state or territory.

Australian Immunisation Register

You must report all meningococcal ACWY vaccines administered to the Australian Immunisation Register (AIR).

National Immunisation Program meningococcal ACWY vaccines by cohort

Check you have the correct NIP funded vaccine for your patient.

1 July 2024 NIP-funded meningococcal ACWY vaccine eligibility

Cohort	Meningococcal ACWY vaccine	
	Nimenrix® 0.50mL (Pfizer)	MenQuadfi® 0.50mL (Sanofi)
Children 12 months of age	✓	
Adolescents 14-19 years of age		✓
Medically at risk	✓	

Note: Other meningococcal ACWY vaccines that are not NIP-funded are available in the Australian market. For further information, refer to the Australian Immunisation Handbook – [Meningococcal disease](#).

Further information

You should read the advice in this factsheet in conjunction with:

- The Australian National Immunisation Program schedule at health.gov.au/immunisation
- The Australian Immunisation Handbook available at immunisationhandbook.health.gov.au

Keep up to date with current information

Subscribe to the NIP updates email distribution list. Search 'NIP updates' at health.gov.au

State and territory health department contact numbers:

ACT 02 5124 9800	SA 1300 232 272
NSW 1300 066 055	TAS 1800 671 738
NT 08 8922 8044	VIC immunisation@health.vic.gov.au
WA 08 9321 1312	QLD Contact your local Public Health Unit



A joint Australian, State and Territory Government Initiative

All information in this fact sheet is correct as of June 2024.